Skip to main content

Table 4 Therapy-associated toxicity by grade per patient

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

EventAny gradeGrade 3Grade ≥ 4
Any toxicity n (%)
 Nausea Nausea11 (34.4)0 (0)0 (0)
 Fatigue16 (50)1 (3.1)0 (0)
 Neutropenia15 (47)2 (6.3)10 (31.3)
 Mucositis6 (18.7)1 (3.1)0 (0)
 Alopecia Alopecia32 (100)0 (0)0 (0)
 Vomiting5 (15.6)0 (0)0 (0)
 Anaemia Anaemia29 (90.6)7 (21.9)0 (0)
 Leukopenia Leukopenia21 (65.6)10 (31.3)2 (6.3)
 Constipation7 (21.9)0 (0)0 (0)
 Diarrhea Diarrhea2 (6.3)0 (0)0 (0)
 Decreased appetite Decreased appetite10 (31.3)0 (0)0 (0)
 Abdominal pain3 (3.4)1 (3.1)1 (3.1)
 Pyrexia3 (9.4)0 (0)2 (6.3)
 Musculoskeletal pain2 (6.3)0 (0)0 (0)
 Febrile neutropenia4 (12.5)1 (3.1)2 (6.3)
 Infections and infestations7 (21.9)1 (3.1)3 (9.4)
 Infusion-related reaction1 (3.1)0 (0)0 (0)
 Olaratumab-related toxicitiy0 (0)0 (0)0 (0)
 Toxicity leading to discontinuation1 (3.1)0 (0)1 (3.1)
 Cardiac dysfunction0 (0)0 (0)0 (0)
  1. Toxicity was assessed according to the National Cancer Institute (NCI) criteria v5.0